neoX Biotech

📍 北京市, China🗓 Founded 2018👥 19 employees💰 Last funded Dec 2020
北京星亢原生物科技有限公司(neoX Biotech)是一家将人工智能(AI)与生物物理相结合,进行药物研发的生物高科技公司。星亢原专注大分子和多特异性分子药物研发,尤其是在肿瘤免疫治疗领域。 针对治疗药物的早期发现,星亢原通过表征蛋白质-蛋白质相互作用(PPI)开发了一个强大的研发平台。星亢原已经与国内外生物医药公司建立合作,布局药物研发管线。 星亢原由美国麻省理工学院和加州理工学院毕业的两位博士创立,核心研发团队来自北京大学、美国莱斯大学、中国科学院、德国亥姆霍兹感染研究中心、默沙东(MSD)等生物医药领域研究机构和跨国药企,团队成员曾在《自然》《科学》《细胞》等国际顶级期刊发表有重大影响力的学术文章,并被媒体报道。公司已经获得了包括红杉资本、五源资本(原晨兴资本)、元璟资本、真格基金、云九资本、祥峰投资、BAI资本在内的顶尖风险投资基金投资。
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2018
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in neoX Biotech?
neoX Biotech has 1 investors on record on gritt.io, including 1 early-stage backers.
When did neoX Biotech last raise funding?
The most recent investment in neoX Biotech recorded on gritt.io was in December 2020.
When was neoX Biotech founded?
neoX Biotech was founded in 2018.
What industry is neoX Biotech in?
neoX Biotech operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is neoX Biotech based?
neoX Biotech is headquartered in 北京市, China.